Zydus Lifesciences Ltd. is ramping up its vaccines and medtech portfolio, positioning itself for double-digit revenue growth in FY26. The pharmaceutical major, which posted its highest-ever operating profit and margins in FY25, sees biologics, vaccines, and medical devices as key drivers of expansion.
Vaccine Strategy & Global Expansion
- Zydus is developing the world’s first combination vaccine for shigellosis and typhoid, backed by the Gates Foundation.
- The company received regulatory approval for Phase 2 trials of its bivalent Typhoid Conjugate Vaccine (TCV).
- It is actively pursuing India’s Measles-Rubella (MR) vaccine tenders and expanding into WHO-prequalified markets.
- Zydus is registering products in Egypt, opening new international opportunities.
Medtech Expansion & Strategic Acquisitions
- Zydus has entered the medtech space with the acquisition of Amplitude Surgical SA, France, strengthening its orthopedic device portfolio.
- The company is building capabilities in nephrology and cardiovascular devices, with some ventures already profitable.
Financial Performance & Market Outlook
- FY25 revenue surged 19% YoY to ₹23,241 crore, with an EBITDA margin of 30.4%.
- FY26 guidance projects an EBITDA margin of 26%, with high single-digit growth in the US market.
- Zydus anticipates continued expansion in emerging markets and Europe, focusing on high-growth therapy areas.
With aggressive expansion in vaccines and medtech, Zydus Lifesciences is set to strengthen its global footprint and drive innovation in healthcare.
For more updates on pharmaceutical trends and corporate earnings, stay tuned!
1xbet spor bahislerinin adresi 1xbet spor bahislerinin adresi .